Item 2.02 Results of Operations and Financial Condition.
On January 14, 2020, Halozyme Therapeutics, Inc., a Delaware corporation
("Halozyme"), issued a press release (the "Press Release") which contained
information related to Halozyme's expected 2019 revenue. A copy of the Press
Release is attached hereto as Exhibit 99.1.
Exhibit 99.1 is furnished under Item 2.02 of this report and shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, (the "Exchange Act") or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, regardless of any
general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description

            Press release
  99.1      dated         January 14, 2020
            Cover Page Interactive Data File (formatted as inline XBRL and
104         contained in Exhibit 101)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses